Background: PDX1 activates insulin, somatostatin, glucokinase, islet amyloid polypeptide and glucose transporter type 2 gene transcription. Particularly involved in glucose-dependent regulation of insulin gene transcription. As part of a PDX1:PBX1b:MEIS2b complex in pancreatic acinar cells is involved in the transcriptional activation of the ELA1 enhancer; the complex binds to the enhancer B element and cooperates with the transcription factor 1 complex (PTF1) bound to the enhancer A element. Binds preferentially the DNA motif 5'-[CT]TAAT[TG]-3'. During development, specifies the early pancreatic epithelium, permitting its proliferation, branching and subsequent differentiation. At adult stage, required for maintaining the hormone-producing phenotype of the beta-cell.
Immunogen: Synthetic peptide derived from human PDX1 protein.
Purification Method: Antigen Immunoaffiinity Purification
Concentration: See vial for concentration
Formulation: Provided as solution in phosphate buffered saline with 0.08% sodium azide
References: 1. Stoffers, D.A., et al. ‘Pancreatic agenesis attributable to a single nucleotide deletion in the human IPF1 gene coding sequence.’ Nat. Genet., 15, 106-110 (1997)2. Macfarlane, M.W., et al. ‘Missense mutations in the insulin promoter factor-1 gene predispose to type 2 diabetes.’ J. Clin. Invest., 104, R33-R39 (1999)3. Hani, E.H., et al. ‘Defective mutations in the insulin promoter factor-1 (IPF-1) gene in late-onset type 2 diabetes mellitus.’ J. Clin. Invest., 104, R41-R48 (1999)4. An, R., et al. ‘Pancreatic and duodenal homeobox 1 (PDX1) phosphorylation at serine-269 is HIPK2-dependent and affects PDX1 subnuclear localization.’ Biochem. Biophys Res. Commun., 399, 155-161 (2010)
UniProt: P52945
Caution: This product is intended FOR RESEARCH USE ONLY, and FOR TESTS IN VITRO, not for use in diagnostic or therapeutic procedures involving humans or animals.